Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

Publication

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

Journal Paper/Review - Nov 25, 2000

Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J C, Boggian Katia, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A

Units

Division of Infectious Diseases, Infection Prevention and Travel Medicine

PubMed

11117912

Citation

Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J, Boggian K, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.

Type

Journal Paper/Review (English)

Journal

Lancet 2000; 356

Publication Date

Nov 25, 2000

Issn Print

0140-6736

Pages

1800-5

Brief description/objective

Hepatitis C virus (HCV) infection is highly prevalent among HIV-1-infected individuals, but its contribution to the morbidity and mortality of coinfected patients who receive potent antiretroviral therapy is controversial. We used data from the ongoing Swiss HIV Cohort Study to analyse clinical progression of HIV-1, and the virological and immunological response to potent antiretroviral therapy in HIV-1-infected patients with or without concurrent HCV infection.